JP2007522200A5 - - Google Patents

Download PDF

Info

Publication number
JP2007522200A5
JP2007522200A5 JP2006552710A JP2006552710A JP2007522200A5 JP 2007522200 A5 JP2007522200 A5 JP 2007522200A5 JP 2006552710 A JP2006552710 A JP 2006552710A JP 2006552710 A JP2006552710 A JP 2006552710A JP 2007522200 A5 JP2007522200 A5 JP 2007522200A5
Authority
JP
Japan
Prior art keywords
alkyl
methyl
ethyl
dimethyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006552710A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007522200A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2005/000251 external-priority patent/WO2005079807A1/en
Publication of JP2007522200A publication Critical patent/JP2007522200A/ja
Publication of JP2007522200A5 publication Critical patent/JP2007522200A5/ja
Pending legal-status Critical Current

Links

JP2006552710A 2004-02-13 2005-02-01 非定型抗精神病薬とコルチコトロピン放出因子拮抗薬の治療的組合せ Pending JP2007522200A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54473104P 2004-02-13 2004-02-13
PCT/IB2005/000251 WO2005079807A1 (en) 2004-02-13 2005-02-01 Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists

Publications (2)

Publication Number Publication Date
JP2007522200A JP2007522200A (ja) 2007-08-09
JP2007522200A5 true JP2007522200A5 (https=) 2008-03-21

Family

ID=34886075

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006552710A Pending JP2007522200A (ja) 2004-02-13 2005-02-01 非定型抗精神病薬とコルチコトロピン放出因子拮抗薬の治療的組合せ

Country Status (14)

Country Link
US (1) US20050209250A1 (https=)
EP (1) EP1718311A1 (https=)
JP (1) JP2007522200A (https=)
KR (1) KR20060110006A (https=)
CN (1) CN1917882A (https=)
AU (1) AU2005215257A1 (https=)
BR (1) BRPI0507609A (https=)
CA (1) CA2556160A1 (https=)
IL (1) IL177433A0 (https=)
NO (1) NO20064054L (https=)
RU (1) RU2006129307A (https=)
TW (1) TW200538128A (https=)
WO (1) WO2005079807A1 (https=)
ZA (1) ZA200606636B (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
EP2170399A1 (en) * 2007-06-05 2010-04-07 Synthon B.V. Intranasal administration of asenapine and pharmaceutical compositions therefor
NZ586418A (en) * 2007-12-19 2012-09-28 Cancer Rec Tech Ltd Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
US20100298397A1 (en) * 2009-05-19 2010-11-25 Singh Nikhilesh N Method of treatment of obsessive compulsive disorder with ondansetron
CA2937222C (en) 2009-06-25 2019-06-04 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds
US8431576B2 (en) 2009-06-25 2013-04-30 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
EP2521711B1 (en) 2010-01-07 2017-08-16 Alkermes Pharma Ireland Limited Quaternary ammonium salt prodrugs
WO2011084849A1 (en) * 2010-01-07 2011-07-14 Alkermes, Inc. Diaryldiazepine prodrugs for the treatment of neurological and psychological disorders
EP2521545B1 (en) 2010-01-07 2019-11-27 Alkermes Pharma Ireland Limited Prodrugs of heteroaromatic compounds
ES2691671T3 (es) 2010-06-24 2018-11-28 Alkermes Pharma Ireland Limited Profármacos de compuestos NH-acídicos: derivados de éster, carbonato, carbamato y fosfonato
US20120302616A1 (en) * 2010-12-03 2012-11-29 Nikhilesh Singh Method of treatment of obsessive compulsive disorder with ondansetron
HUE065359T2 (hu) 2011-03-18 2024-05-28 Alkermes Pharma Ireland Ltd Szorbitán-észtereket tartalmazó gyógyászati készítmények
JP5952912B2 (ja) 2011-12-15 2016-07-13 アルカーメス ファーマ アイルランド リミテッド 二級アミン化合物のプロドラッグ
ES2950418T3 (es) 2012-03-19 2023-10-09 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden alcohol bencílico
ES2765036T3 (es) 2012-03-19 2020-06-05 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden esteres de ácidos grasos
JP6219918B2 (ja) 2012-03-19 2017-10-25 アルカームス ファーマ アイルランド リミテッド グリセロールエステルを含む医薬組成物
EP2897592B1 (en) 2012-09-19 2020-02-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
RS65839B1 (sr) 2014-01-21 2024-09-30 Neurocrine Biosciences Inc Crf1 receptor antagonisti za tretman kongenitalne adrenalne hiperplazije
BR112016021535A8 (pt) 2014-03-20 2021-07-20 Alkermes Pharma Ireland Ltd kit compreendendo formulações de aripiprazol tendo velocidades de injeção aumentadas útil para o tratamento de uma desordem do sistema nervoso central e uso
JP7187037B2 (ja) * 2016-09-07 2022-12-12 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア p-タウを減少させ、認知機能を改善させるアロステリック副腎皮質刺激ホルモン放出因子受容体1(CRFR1)アンタゴニスト
CN115813888A (zh) 2016-12-20 2023-03-21 罗曼治疗系统股份公司 包含阿塞那平的透皮治疗系统
EP3558276B1 (en) 2016-12-20 2024-11-06 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
WO2019002204A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER
EP3664806B1 (en) * 2017-08-09 2025-04-30 Sanford Burnham Prebys Medical Discovery Institute 3-PHENYL-PYRAZOLO[1,5-A]PYRIMIDINE-5-CARBOXILIC ACID DERIVATIVES AS APELIN (APJ) RECEPTOR AGONISTS FOR THE TREATMENT OF CARDIOVASCULAR, METABOLIC, CNS, OR INFECTIOUS DISEASES OR DISORDERS
WO2019036503A1 (en) 2017-08-14 2019-02-21 Spruce Biosciences, Inc. CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS
EP3761983A1 (en) 2018-03-05 2021-01-13 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
EP4643950A3 (en) 2018-04-27 2026-01-14 Spruce Biosciences, Inc. Methods for treating testicular and ovarian adrenal rest tumors
US12329862B2 (en) 2018-06-20 2025-06-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
AU2019291060B2 (en) 2018-06-20 2024-09-05 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US20220023266A1 (en) 2018-12-07 2022-01-27 Neurocrine Biosciences, Inc. Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
JP7623365B2 (ja) 2019-09-27 2025-01-28 ニューロクライン バイオサイエンシーズ,インコーポレイテッド Crf受容体アンタゴニストおよび使用方法
KR20240023691A (ko) 2020-08-12 2024-02-22 스프루스 바이오사이언시스 인코포레이티드 다낭성 난소 증후군을 치료하기 위한 방법 및 조성물
US20250276066A1 (en) * 2021-02-10 2025-09-04 Gero Pte. Ltd. Methods, compositions and compounds for treating age-related diseases and conditions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7605526A (nl) * 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
TW530047B (en) * 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
TW477787B (en) * 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
EP1040831A3 (en) * 1999-04-02 2003-05-02 Pfizer Products Inc. Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
US6432989B1 (en) * 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders

Similar Documents

Publication Publication Date Title
JP2007522200A5 (https=)
RU2006129307A (ru) Терапевтические комбинации атипичных нейролептиков с антагонистами кортикотропин-рилизинг фактора
AU776077B2 (en) Use of CRF antagonists and related compositions
RU2221799C2 (ru) Антагонисты кортикотропин-рилизинг фактора
JP2022527796A5 (https=)
JP2022184886A5 (https=)
US20010041673A1 (en) Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues
AU776724B2 (en) Use of corticotropin releasing factor antagonists and related compositions
JP2018529731A5 (https=)
JPH09132528A (ja) コルチコトロピン放出因子アンタゴニストの新規使用
JP2020504136A5 (https=)
RU2007134899A (ru) ПРОИЗВОДНЫЕ АЦЕТИЛЕНИЛ-ПИРАЗОЛО-ПИРИМИДИНА В КАЧЕСТВЕ АНТАГОНИСТОВ mGLuR2
RU97100192A (ru) Антагонисты кортикотропин-рилизинг фактора
JP2016537384A5 (https=)
JP2005500315A5 (https=)
JP2017515848A5 (https=)
JP2007523151A5 (https=)
JP2004527560A5 (https=)
AU2263400A (en) QT dispersion and heart rate variability improvement with CRF antagonists to prevent sudden death
JP2013500247A5 (https=)
JP2015508075A5 (https=)
JP2019536768A5 (https=)
JP2019503337A5 (https=)
RU2014151004A (ru) Пирролопиримидоновые и пирролопиридоновые ингибиторы танкиразы
RU2014126750A (ru) Ингибиторы тирозинкиназы брутона